Skip to main content
. Author manuscript; available in PMC: 2010 Aug 10.
Published in final edited form as: Biol Blood Marrow Transplant. 2009 Oct 12;16(2):263–272. doi: 10.1016/j.bbmt.2009.10.005

Table 2.

GVHD after HLA-Identical Sibling BMT for Sickle Cell Disease

Patient No. aGVHD (Grade/Site) cGVHD (Grade/Site) Treatment Outcome
1 II/skin Limited/skin CsA/pred resolved
9 III/skin Extensive/lung, liver CsA/Pred Died of GVHD
27 None Limited/skin none resolved
30 III/skin, GI, liver Extensive/GI, liver CsA/Pred/ATG/thalidomide Died of GVHD
34 III/skin, GI, liver Limited/oral CsA/Pred resolved
35 III/skin, GI, liver Extensive/skin, liver, GI CsA/tacrolimus/MMF/ATG/OKT3/sirolimus resolved
41 III/skin Extensive/skin, lung, oral Tacrolimus/pred/MMF/azathioprine Died of GVHD
51 II/skin Limited/skin CsA/pred resolved

aGVHD indicates acute graft-versus-host disease; ATG, antithymocyte globulin; BMT, bone marrow transplantation; cGVHD, chronic graft-versus-host disease; CsA, cyclosporine; GI, gastrointestinal; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; Pred, prednisone.